LPG 18:0 是哮喘通用生物标志物并抑制调节性 T 细胞分化与功能
该研究通过脂质组学分析哮喘患者与对照者血清甘油磷脂谱,发现 LPG 18:0 在哮喘患者中显著升高,并与哮喘严重程度和控制水平相关。体内外实验表明 LPG 18:0 通过 NAD+/SIRT1/FOXP3 通路损害调节性 T 细胞分化和抑制功能,提示其作为哮喘生物标志物及治疗靶点的潜力。
要点
- 哮喘患者血清 LPG 18:0 水平显著升高,与严重程度和控制水平相关
- LPG 18:0 损害初始 CD4+ T 细胞向 Treg 分化并削弱其抑制功能
- LPG 18:0 通过 SIRT1 介导去乙酰化降低 Treg 中 FOXP3 蛋白水平
核心结论
- 血清 LPG 18:0 在哮喘患者中普遍升高,可作为哮喘生物标志物。
- LPG 18:0 通过 NAD+/SIRT1/FOXP3 通路损害 Treg 功能。
研究设计与样本
- 研究采用脂质组学分析哮喘患者与对照者血清甘油磷脂谱。
- 使用小鼠哮喘模型在体内验证 LPG 18:0 作为生物标志物的潜力并探究机制。
- 体外通过流式细胞术评估 LPG 18:0 对 CD4+ T 细胞分化、增殖和凋亡的影响。
主要发现
- 哮喘患者与对照者血清甘油磷脂谱存在差异,哮喘患者 LPG 18:0 水平显著升高。
- LPG 18:0 水平与哮喘严重程度和控制水平相关。
- LPG 18:0 损害初始 CD4+ T 细胞向 Treg 分化并削弱其抑制功能。
- LPG 18:0 通过 SIRT1 介导去乙酰化降低 Treg 分化过程中 FOXP3 蛋白水平。
临床怎么用
- LPG 18:0 有望作为哮喘诊断和病情评估的血清生物标志物。
- 靶向 LPG 18:0 及其下游 NAD+/SIRT1/FOXP3 通路可能为哮喘治疗提供新策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The diagnosis, severity assessment, and development of therapeutic strategies for asthma are crucial aspects of disease management. Since biomarkers are reliable tools in disease management, we aimed to identify and explore asthma-associated biomarkers and investigate their mechanisms. METHODS: Lipidomics was used to profile serum glycerophospholipids in asthmatic patients and controls. The absolute concentration of lysophosphatidylglycerol (LPG) 18:0 was quantified in various asthma subtypes. Mouse asthma models were used to confirm its potential as a biomarker and investigate its mechanisms in vivo. The effects of LPG 18:0 on CD4+ T-cell differentiation, proliferation and apoptosis were assessed in vitro by flow cytometry, while mitochondrial dysfunction was evaluated through mitochondrial membrane potential, reactive oxygen species and ATP production measurements. The intracellular mechanism of LPG 18:0 in regulatory T-cells (Tregs) was investigated using small-molecule inhibitors. RESULTS: The serum glycerophospholipid profile varied between asthmatic patients and control group, with LPG 18:0 levels being notably higher in asthmatic patients, correlating with asthma severity and control level. In vivo and in vitro studies revealed that LPG 18:0 impaired naïve CD4+ T-cell differentiation into Tregs and compromised their suppressive function. Further investigation demonstrated that LPG 18:0 treatment reduced the FOXP3 protein level via SIRT1-mediated deacetylation during Treg differentiation. CONCLUSIONS: This study identifies that serum levels of LPG 18:0 are generally elevated in asthmatics and serve as a biomarker for asthma. LPG 18:0 impairs Treg function via the NAD+/SIRT1/FOXP3 pathway. Our research reveals the potential of LPG 18:0 as a biomarker for asthma, elucidating its role in asthma diagnosis and treatment.
引用
- Aili A, Wang Y, Shang Y, et al. LPG 18:0 is a general biomarker of asthma and inhibits the differentiation and function of regulatory T-cells. Eur Respir J. 2024. PMID: 39147414. doi:10.1183/13993003.01752-2023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。